Polivy Market Report 2026

Polivy Market Overview

• The Polivy market growth in the historic period has been driven by increasing incidence of diffuse large b-cell lymphoma, advancements in monoclonal antibody development • Market expansion is supported by increasing demand for personalized oncology drugs, rising investments in adc research pipelines • Growth Driver: Growing Incidence Of Diffuse Large B-Cell Lymphoma Boosts Demand For Polivy • Market Trend: Adoption of First-Line Antibody-Drug Conjugate Combinations in Polivy Market to Improve DLBCL Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Polivy Market?

Polivy (polatuzumab vedotin) is an antibody-drug conjugate used for the treatment of diffuse large B-cell lymphoma, which is a type of non-Hodgkin lymphoma. It is specifically indicated for adult patients with relapsed or refractory diffuse large B-cell lymphoma after they have undergone at least two prior therapies. Additionally, it can be used as a first-line treatment in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for patients with moderate- to high-risk diffuse large B-cell lymphoma. The main indications of polivy are previously untreated diffuse large b-cell lymphoma, relapsed or refractory diffuse large b-cell lymphoma. Previously untreated diffuse large B-cell lymphoma is a form of cancer affecting white blood cells that have not received any prior treatment. It is typically aggressive and requires prompt medical intervention. Polivy is used as part of combination therapy to address this condition effectively. It is dose in the form of injectable solutions and distributed through various channels such as direct sales, pharmaceutical wholesalers, and online pharmacies.

What Is The Polivy Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for personalized oncology drugs, rising investments in adc research pipelines, expansion of first-line combination therapies, growing focus on treatment-resistant lymphomas, increasing regulatory approvals for targeted biologics. Major trends in the forecast period include increasing adoption of antibody-drug conjugates, rising use in targeted lymphoma therapies, growing integration with combination chemotherapy regimens, expansion of precision oncology treatments, enhanced focus on cd79b-targeted drugs.

What Are The Drivers Of The Polivy Market?

The increasing incidence of diffuse large B-cell lymphoma is expected to propel the growth of the polivy market going forward. Diffuse large B-cell lymphoma (DLBCL), the most prevalent type of non-hodgkin lymphoma (NHL), is classified as a highly aggressive blood cancer that originates from B-lymphocytes, which are white blood cells essential for the immune system's function of producing antibodies to combat infections. The increasing incidence of diffuse large B-cell lymphoma can be attributed to several factors, including an aging population, rising rates of immunosuppression due to conditions such as HIV/AIDS and organ transplants, and environmental exposures that contribute to the disease's etiology. Polivy is used in combination with chemotherapy to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients who have received prior treatments. For instance, in July 2024, according to a report published by the Royal College of Pathologists, a UK-based professional membership organization, each year in the UK, approximately 5,500 individuals are diagnosed with diffuse large B-cell lymphoma (DLBCL), which is a highly aggressive form of non-Hodgkin lymphoma. About 30% of these patients will experience refractory disease or relapse shortly after their initial treatment. Therefore, the increasing incidence of diffuse large B-cell lymphoma is driving the growth of the polivy industry. The rising number of oncology procedures is expected to propel the growth of the polivy market going forward. Oncology procedures refer to medical tests, treatments, and interventions performed to diagnose, manage, and treat various types of cancer. Oncology procedures are increasing as more healthcare providers and patients prioritize early cancer detection and access to effective targeted therapies. Polivy plays a crucial role in the rising number of oncology procedures by offering targeted therapy that improves outcomes and expands treatment options for cancer patients. For instance, in February 2024, according to the World Health Organization, a US-based United Nations agency, reported that over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the rising number of oncology procedures is driving the growth of the polivy industry.

Key Players In The Global Polivy Market

Major companies operating in the polivy market are F. Hoffmann-La Roche Ltd (Genentech Inc.)

Global Polivy Market Trends and Insights

Major companies operating in the polivy market are focusing on developing innovative regimens, such as first-line antibody-drug conjugate (ADC) combinations, to better target aggressive B-cell lymphomas and improve patient outcomes. A first-line ADC combination integrates a monoclonal antibody that selectively binds to tumor-specific proteins with a cytotoxic payload, enabling highly targeted therapy, unlike conventional chemotherapy, which affects both cancerous and healthy cells. For instance, in April 2023, Genentech, a U.S.-based biotechnology company, received FDA approval for Polivy (polatuzumab vedotin-piiq) in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) for previously untreated diffuse large B-cell lymphoma (DLBCL) in adults. Polivy is a first-in-class anti-CD79b ADC developed using Seagen’s linker-payload technology: the antibody targets the CD79b protein on B-cells, the conjugated payload (vedotin) is a potent microtubule-disrupting agent, and upon binding the drug is internalized into the cancer cell where the cytotoxic agent is released to induce cell death. Its unique features include high specificity toward malignant B-cells, a more favorable safety profile compared to systemic chemotherapy, and a demonstrated 27% reduction in risk of progression or death versus standard R-CHOP in the pivotal POLARIX study. This combination is now poised to transform first-line treatment in DLBCL, potentially reducing relapse rates and alleviating long-term patient burden.

What Defines the Polivy Market?

The polivy market consists of sales of polivy (polatuzumab vedotin) injections in 30 mg and 140 mg vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Polivy Market Report 2026?

The polivy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the polivy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.